📰 Avidity Bioscience News
Avidity Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Avidity Bioscience. Real-time updates on events, politics, business and more.
June 13, 2024
Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles.
October 1, 2023
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
July 20, 2023
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) and Avidity Biosciences (NASDAQ:RNA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends. Earnings & Valuation This table compares KalVista […]
May 17, 2023
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Rating) – Chardan Capital dropped their FY2023 EPS estimates for Avidity Biosciences in a report released on Wednesday, May 10th. Chardan Capital analyst K. Nakae now forecasts that the biotechnology company will earn ($2.94) per share for the year, down from their prior forecast of ($2.90). Chardan Capital currently […]